Lifitegrast Ophthalmic Solution – A Review

S. Padmaja a# and K. Lakshitha Niyatee Rao a†

a Department of Pharmacology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India.

Authors' contributions
This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Article Information
DOI: 10.9734/JPRI/2021/v33i57A33984
Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/76633

Received 06 October 2021
Accepted 13 December 2021
Published 14 December 2021

ABSTRACT

Introduction: In this review article the safety and efficacy of of Lifitegrast™ in the management of dry eye disease is described.

Methods: Search was carried out using related search terms in data bases like pubmed and related articles were referred.

Result: A larger reduction in Eye dryness Score (EDS) was seen with Lifitegrast™.

Conclusion: Lifitegrast™ ophthalmic solution 5% provides a new option for the treatment of dry eyes.

Keywords: Lifitegrast™; eye dryness; drug complication.

1. INTRODUCTION

Lifitegrast™ is approved by USFDA on June 2016 to treat signs and symptoms of the dry disease. It belongs to lymphocyte associated antigen-1 (LFA-1) antagonist. Lifitegrast™ reduces the swelling in the eye tissues.

2. INDICATIONS

It is indicated in treatment of dry eye disease.

3. DOSAGE FORMS

Ophthalmic solution containing lifitegrast™ 5% (50 mg/mL).
4. MECHANISM OF ACTION

A cell surface protein found on leucocytes which is an integrin lymphocyte function-associated antigen-1 (LFA-1). Lifitegrast™ binds to LFA-1 and blocks the interaction of LFA-1 with its ligand ICAM-1 (intracellular adhesion molecule-1). Interaction of LFA-1/ICAM-1 leads to formation of an immunological synapse resulting in T-cell activation and migration to target tissues [1].

5. NONCLINICAL TOXICOLOGY

Carcinogenesis – Studies have not been conducted in the animals to assess the carcinogenicity.

6. MUTAGENICITY

Lifitegrast™ was not found to be mutagenic in vitro assay.

7. IMPAIRED FERTILITY

Lifitegrast™ had no effect on fertility and reproduction in male and female treated rats after administering intravenous doses of lifitegrast™ at 30mg/kg/day [2].

8. ADVERSE EFFECTS

The most common adverse effects commonly reported in a study with 1401 patients 5-25% of them had instillation site irritation, reduced visual acuity and dysgeusia. Other 1-5% of patients experienced headache, blurring of vision, eye pruritus with sinusitis [3].

9. DRUG INTERACTIONS

No significant interaction with other drugs.

10. USES IN SPECIFIC POPULATION: PREGNANCY

There are no data available for studies related to pregnant women. Lifitegrast™ administered to rats during their gestational period did not produce any embryofetal defects [4]. When given to pregnant rabbits there were increased incidence of omphalocele at the lowest dose tested, 3mg/kg/day [1].

11. LACTATION

There are no reliable data available on presence of lifitegrast™ in breast milk.

12. PEDIATRIC POPULATION

Safety and efficacy of Lifitegrast™ in pediatric patients below the age of 17 years have not been established [1].

13. GERIATRIC

overall there is no difference in safety or effectiveness of Lifitegrast™ between elderly and younger adult patients [1].

14. CLINICAL STUDIES

Totally 1181 patients were recruited to study the safety and efficacy of Lifitegrast™ for the treatment of dry eyes. The study was conducted for 12 weeks and it was a randomized, multi-centre, double blinded trial. Patients were randomization in 1:1 ratio and received either Lifitegrast™ or placebo. patients were dosed twice a day and use of artificial tears was not allowed.

Eye dryness Score (EDS) was assessed by patients using a visual analogue scale (VAS) (0 = no discomfort, 100 = maximal discomfort) during each study visit. The average baseline EDS was between 40 and 70. A larger reduction in EDS favouring lifitegrast™ was observed in all studies at Day 42 and Day 84 [5].

15. CONCLUSION

Lifitegrast™ ophthalmic solution 5% provides a new option for the treatment of dry eyes.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCE

